Key result
Serum osteoprotegerin linked to peripheral arterial stiffness in patients with CKD.
Why the study?
Peripheral arterial stiffness is prevalent in CKD and contributes to cardiovascular risk, prompting investigation into whether circulating osteoprotegerin is associated with it.
Is circulating osteoprotegerin associated with peripheral arterial stiffness in patients with chronic kidney disease?
Is circulating osteoprotegerin associated with peripheral arterial stiffness in patients with chronic kidney disease?
This study investigates the potential role of circulating osteoprotegerin as a biomarker for peripheral arterial stiffness in chronic kidney disease.
Should not yet guide clinical decisions in CKD; leaves open osteoprotegerin’s biomarker role for arterial stiffness pending prospective validation.
Peripheral arterial stiffness (PAS) is prevalent in chronic kidney disease (CKD) and contributes to cardiovascular risk. We investigated whether circulating osteoprotegerin (OPG), a cytokine linked to vascular calcification, is associated with PAS assessed by brachial-ankle pulse wave velocity (baPWV) in CKD.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question. Serum osteoprotegerin is independently associated with peripheral arterial stiffness, assessed by brachial-ankle pulse wave velocity, in patients with chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: